(Q34294851)

1 August 2017

1 reference

title

Prevention and treatment of cytomegalovirus infection in organ transplant recipients (English)

1 reference

1 August 2017

0 references

cytomegaloviral disease

1 reference

3

Fung J

2 references

1 August 2017

ORCID Public Data File 2021

author name string

Kusne S

series ordinal

1

1 reference

1 August 2017

Shapiro R

series ordinal

2

1 reference

1 August 2017

language of work or name

1 reference

1 September 1999

1 reference

Transplant Infectious Disease

1 August 2017

published in

1 reference

1 August 2017

volume

1

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

187-203

1 reference

Increased Pulmonary Superinfections in Cardiac-Transplant Patients Undergoing Primary Cytomegalovirus Infection

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Posttransplant Lymphoproliferative Disease in Primary Epstein‐Barr Virus Infection after Liver Transplantation: The Role of Cytomegalovirus Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. A trial of ganciclovir vs immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Comparison of Intravenous Ganciclovir Followed by Oral Acyclovir with Intravenous Ganciclovir Alone for Prevention of Cytomegalovirus and Epstein‐Barr Virus Disease After Liver Transplantation in Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Randomized Comparison of Ganciclovir Plus Intravenous Immune Globulin (IVIG) with IVIG Alone for Prevention of Primary Cytomegalovirus Disease in Children Receiving Liver Transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Surveillance cultures of blood, urine, and throat specimens are not valuable for predicting cytomegalovirus disease in liver transplant recipients. Boston Center for Liver Transplantation Cytomegalovirus Immune Globulin Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Nuclear expression of the lower matrix protein of human cytomegalovirus in peripheral blood leukocytes of immunocompromised viraemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Detection of human cytomegalovirus antigenaemia: a rapid diagnostic technique for predicting cytomegalovirus infection/pneumonitis in lung and heart transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Treatment of recurrent cytomegalovirus disease in patients receiving solid organ transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Prevalence of Resistance in Patients Receiving Ganciclovir for Serious Cytomegalovirus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Diagnosis and Treatment of Cytomegalovirus Disease in Transplant Patients Based on Gastrointestinal Tract Manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Combined antibody and ganciclovir treatment of murine cytomegalovirus-infected normal and immunosuppressed BALB/c mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Community-acquired Acinetobacter pneumonia in the Northern Territory of Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

PREEMPTIVE TREATMENT FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

Cytomegalovirus infection persists in the liver graft in the vanishing bile duct syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Cytomegalovirus disease is associated with increased cost and hospital length of stay among orthotopic liver transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Preemptive Therapy in Immunocompromised Hosts

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients. The Nordic BMT Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Controlled trial of prophylactic versus therapeutic use of ganciclovir after liver transplantation in adults

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Prevention of cytomegalovirus-related death by passive immunization. A double-blind placebo-controlled study in kidney transplant recipients treated for rejection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Intravenous immunoglobulin infusions for the prophylaxis of secondary cytomegalovirus infection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients. A randomized trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Cytomegalovirus PP65 antigenemia monitoring as a guide for preemptive therapy: a cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

The prognostic significance of positive CMV cultures during surveillance of renal transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Quantitative analysis of cytomegalovirus viremia in lung transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Comparative study of cytomegalovirus (CMV) antigenemia assay, polymerase chain reaction, serology, and shell vial assay in the early diagnosis and monitoring of CMV infection after renal transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Association of quantitative cytomegalovirus antigenemia with symptomatic infection in solid organ transplant patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Antigenemia in the Diagnosis and Monitoring of Active Cytomegalovirus Infection after Liver Transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Monitoring for cytomegalovirus infection in organ transplant recipients: analysis of pp65 antigen, DNA and late mRNA in peripheral blood leukocytes

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

The correlation between symptomatic CMV infection and CMV antigenemia in heart allograft recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Lack of reactivity to CMV pp65 antigenemia testing in a patient with CMV disease following allogeneic bone marrow transplant

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, and DNAemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Significance of human cytomegalovirus DNA detection in immunocompromised heart transplant patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

The long persistence of CMV DNA in the blood of renal transplant patients after recovery from CMV infection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Clinical patterns of cytomegalovirus disease after liver transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Maturation of antibody avidity after primary human cytomegalovirus infection is delayed in immunosuppressed solid organ transplant patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Prediction of recurrent cytomegalovirus disease after treatment with ganciclovir in solid-organ transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Recovery from cytomegalovirus infection is associated with activation of peripheral blood lymphocytes.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Development of ganciclovir resistance during treatment of primary cytomegalovirus infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Ganciclovir resistance as a result of oral ganciclovir in a heart transplant recipient with multiple human cytomegalovirus strains in blood

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Management of cytomegalovirus disease with antiviral drugs

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection: experience in 314 immunocompromised patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Gastrointestinal cytomegalovirus infection in heart and heart-lung transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Efficacy of ganciclovir in liver and kidney transplant recipients with severe cytomegalovirus infection.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Cytomegalovirus immunoglobulins in the prevention and treatment of cytomegalovirus disease.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Treatment of Interstitial Pneumonitis Due to Cytomegalovirus with Ganciclovir and Intravenous Immune Globulin: Experience of European Bone Marrow Transplant Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.1999.010307.X

7 January 2021

10.1034/J.1399-3062.1999.010307.X

Identifiers

DOI

1 reference

1 August 2017

1 reference